Therapeutic Advances in Drug Safety

Papers
(The TQCC of Therapeutic Advances in Drug Safety is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)
ArticleCitations
Development and psychometric assessment of self-reported patient medication safety scale (SR-PMSS)42
Association between number of medications and indicators of potentially inappropriate polypharmacy: a population-based cohort of older adults in Quebec, Canada39
Survival outcomes of beta-blocker usage in HER2-positive advanced breast cancer patients: a retrospective cohort study28
Enhancing pharmacovigilance for robust drug safety monitoring: addressing underreporting and collaborative solutions27
Acceptability of a cross-sectoral hospital pharmacist intervention for patients in transition between hospital and general practice: a mixed methods study18
Patient-centered pharmacovigilance: priority actions from the inherited bleeding disorders community18
Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database17
Medication errors by caregivers in the homes of children discharged from a pediatric department in Ghana16
Factors related to dosing frequency and route of administration in methotrexate intolerance among patients with rheumatoid arthritis: a cross-sectional study15
Semaglutide: a gendered phenomenon—women’s increased vulnerability to adverse drug reactions in the global weight loss trend15
A critical opinion-based review of hospital pharmacy compounding with respect to the risk of leachable substances due to the off-label use of plastic primary packaging13
Corrigendum13
Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: a population-based survey12
Safety monitoring of oral iron supplements in pregnant women with anemia: a multi-center observational clinical study12
Incidence of antibody–drug conjugate-related hepatotoxicity in breast cancer: a systematic review and meta-analysis12
Increasing patient involvement through self-administration of medication11
Risk communication on vaccines during the COVID19 pandemic: is there room for small size or private initiatives? An Israeli experience10
Implementation of electronic distribution of Direct Healthcare Professional Communications by the Danish Medicines Agency: a survey study of physicians’ experiences and preferences9
Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review9
Impact of risk communication on patient’s safety during the pandemic8
The evolution of the Pharmacovigilance department in the pharmaceutical industry: results of an Italian national survey8
Exploring the community pharmacist’s knowledge, attitude, and practices regarding adverse drug reactions and its reporting in the United Arab Emirates: a survey-based cross-sectional study8
Artificial intelligence in drug development: reshaping the therapeutic landscape7
Patient-centric decision-making in supplements intake and disclosure in clinical practice: a novel SIDP-12 tool to prevent drug–supplement interaction7
The American Program in Pharmacovigilance (Am2P): a new accredited online training program in pharmacovigilance and pharmacoepidemiology7
Drug interactions in patients with alcohol use disorder: results from a real-world study on an addiction-specific ward6
A survey on self-medication for the prevention or treatment of COVID-19 and distrust in healthcare of veterans in a primary care setting in the United States6
Self-medication and the ‘infodemic’ during mandatory preventive isolation due to the COVID-19 pandemic6
Flow rate accuracy of infusion devices within healthcare settings: a systematic review5
Navigating pharmacokinetic and pharmacodynamics challenges of β-lactam antibiotics in patients with low body weight: efficacy, toxicity, and dosage optimization5
Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system5
Clinical relevance of potential self-medication drug interactions in antineoplastic and immune-modulating therapy among online pharmacy customers5
Adverse drug events associated with capecitabine: a real-world pharmacovigilance study based on the FAERS database5
Physiologically based pharmacokinetic modeling of candesartan to predict the exposure in hepatic and renal impairment and elderly populations5
Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database4
Seizure following in-office lidocaine administration: a case report on local anesthetic systemic toxicity4
A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn’s disease4
The crucial role of pharmacovigilance in managing infectious diseases in lower and middle-income countries4
Is there a risk of esketamine misuse in clinical practice?4
Analysis of the nature and contributory factors of medication safety incidents following hospital discharge using National Reporting and Learning System (NRLS) data from England and Wales: a multi-met4
Trends in potentially inappropriate opioid prescribing and associated risk factors among Korean noncancer patients prescribed non-injectable opioid analgesics4
Drug safety of frequently used drugs and substances for self-medication in COVID-194
Funding and financial sustainability of pharmacovigilance: suggested models for funding pharmacovigilance in resource-limited African countries4
Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists: a meta-analysis of 2 million patients4
Comparison of a single intravenous infusion of alfentanil or sufentanil combined with target-controlled infusion of propofol for daytime hysteroscopy: a randomized clinical trial4
A post-marketing disproportionality analysis of the safety of ribociclib based on the FDA Adverse Event Reporting System4
0.021327018737793